Breast fine needle aspiration (FNA) biopsy accounted for 6% of surgical pathology and FNA claims reviewed from 1995-97. The majority of these claims were for false negative breast FNA resulting from sampling error in a woman with a palpable breast mass. Controversies concerning the definition of specimen adequacy for breast FNA are discussed and a strategy for minimizing the management and liability consequences of the problem is proposed. Claims for false positive breast FNA usually result from interpretive error.
1. Troxel D, Sabella J.Problem areas in pathology practice uncovered by a review of malpractice claims. Am J Surg Pathol17:821-831, 1994
2.
2. Layfield LJ, Mooney EE, Glasgow B, Hirschowitz S, Coogan A.What constitutes an adequate smear in fine-needle aspiration cytology of the breast?Cancer (Cancer Cytopathol)81:16-21, 1997
3.
3. Boerner S, Sneige N.Specimen adequacy and falsenegative diagnosis rate in fine-needle aspirates of palpable breast masses. Cancer (Cancer Cytopathol)84:344-348, 1998
4.
4. Abele J, Stanley MW, Rollins SD, Miller TR. What constitutes an adequate smear in fine-needle aspiration cytology of the breast?Cancer (Cancer Cytopathol)84:57-61, 1998
5.
5. Abele JS, Wagner LT, Miller TR. Fine-needle aspiration of the breast: Cell counts as an illusion of adequacy-a clinical cytopathologist's point of view. Cancer (Cancer Cytopathol)84:319-323, 1998
6.
6. NCI-sponsored Bethesda conference 1996: The uniform approach to breast fine-needle aspiration biopsy. Diagn Cytopathol 6:295-311, 1997
